We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| HUTCHMED China Limited | NASDAQ:HCM | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | |
|---|---|---|---|---|---|
| 0.00 | 0.00% | 18.41 | 18.57 | 18.65 |
| High Price | Low Price | Open Price | Traded | Last Trade |
|---|---|---|---|---|
| 125 | 14:13:13 |
| Date | Time | Source | Headline |
|---|---|---|---|
| 11/1/2024 | 07:00 | RNSNON | Hutchmed (China) Limited Sovleplenib NDA Granted Priority Review in China |
| 13/12/2023 | 07:00 | RNSNON | Hutchmed (China) Limited Completed Enrollment of Phase II/III Trial |
| 01/12/2023 | 07:00 | RNSNON | Hutchmed (China) Limited Clinical Data to be Presented at Congresses |
| 16/10/2023 | 09:30 | RNSNON | Hutchmed (China) Limited Clinical Data to be Presented at ESMO 2023 |
| 29/9/2023 | 09:30 | RNSNON | Hutchmed (China) Limited NDA Submission for Fruquintinib in Japan |
| 12/9/2023 | 09:30 | RNSNON | Hutchmed (China) Limited Phase IIIb Savolitinib Results at WCLC 2023 |
| 12/9/2023 | 07:00 | RNSNON | Hutchmed (China) Limited Patient Enrollment Completed for Bridging Study |
| 29/8/2023 | 07:00 | RNSNON | Hutchmed (China) Limited BTD in China for Savolitinib for Gastric Cancer |
| 20/7/2023 | 07:00 | RNSNON | Hutchmed (China) Limited Breakthrough Therapy Designation for Fruquintinib |
| 10/7/2023 | 07:00 | RNSNON | Hutchmed (China) Limited Phase 1 Study of HMPL-415 Initiated |
1 Year HUTCHMED China Chart |
Intraday HUTCHMED China Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
